PharmGKB very important pharmacogene: SLCO1B1.
作者信息
Oshiro Connie, Mangravite Lara, Klein Teri, Altman Russ
机构信息
Department of Genetics, Stanford University, CA, USA.
出版信息
Pharmacogenet Genomics. 2010 Mar;20(3):211-6. doi: 10.1097/FPC.0b013e328333b99c.
Abstract
摘要
相似文献
1
PharmGKB very important pharmacogene: SLCO1B1.药物基因组知识库（PharmGKB）非常重要的药物基因：有机阴离子转运多肽1B1（SLCO1B1）
Pharmacogenet Genomics. 2010 Mar;20(3):211-6. doi: 10.1097/FPC.0b013e328333b99c.
2
Impact of OATP transporters on pharmacokinetics.有机阴离子转运多肽（OATP）转运体对药代动力学的影响。
Br J Pharmacol. 2009 Oct;158(3):693-705. doi: 10.1111/j.1476-5381.2009.00430.x. Epub 2009 Sep 25.
3
Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15.日本受试者中编码转运蛋白OATP1B1的SLCO1B1的基因变异及主要单倍型频率：SLCO1B1*17比*15更常见。
Drug Metab Pharmacokinet. 2007 Dec;22(6):456-61. doi: 10.2133/dmpk.22.456.
4
Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.芬兰人群中有机阴离子转运多肽1B1（SLCO1B1）基因单核苷酸多态性和单倍型的频率
Eur J Clin Pharmacol. 2006 Jun;62(6):409-15. doi: 10.1007/s00228-006-0123-1. Epub 2006 Apr 21.
5
PharmVar GeneFocus: CYP2D6.PharmVar 基因焦点：CYP2D6。
Clin Pharmacol Ther. 2020 Jan;107(1):154-170. doi: 10.1002/cpt.1643. Epub 2019 Dec 9.
6
Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.有机阴离子转运多肽 1B1：一种遗传多态性转运体，对肝脏药物摄取具有重要意义。
Pharmacol Rev. 2011 Mar;63(1):157-81. doi: 10.1124/pr.110.002857. Epub 2011 Jan 18.
7
SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine.坦桑尼亚人、埃塞俄比亚人和欧洲人之间的SLCO1B1基因变异：对非洲和全球精准医学的意义。
OMICS. 2016 Sep;20(9):538-45. doi: 10.1089/omi.2016.0119.
8
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.药物遗传学中的罕见与常见变异：SLCO1B1 变异与甲氨蝶呤处置。
Genome Res. 2012 Jan;22(1):1-8. doi: 10.1101/gr.129668.111. Epub 2011 Dec 6.
9
Pharmacogenetics of membrane transporters: a review of current approaches.膜转运蛋白的药物遗传学：当前方法综述
Methods Mol Biol. 2008;448:41-62. doi: 10.1007/978-1-59745-205-2_4.
10
The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.临床药物基因组学实施联盟关于SLCO1B1与辛伐他汀所致肌病的指南：2014年更新版
Clin Pharmacol Ther. 2014 Oct;96(4):423-8. doi: 10.1038/clpt.2014.125. Epub 2014 Jun 11.
引用本文的文献
1
Impacts of Pharmacokinetic Gene Polymorphisms on Steady-State Plasma Concentrations of Simvastatin in Thai Population.药代动力学基因多态性对泰国人群中辛伐他汀稳态血浆浓度的影响。
Clin Transl Sci. 2025 May;18(5):e70225. doi: 10.1111/cts.70225.
2
Evaluation of pharmacogenomic testing to identify cytochrome P450 and SLCO1B1 enzymes and adverse drug events: A non-experimental observational research.评估药物基因组检测以识别细胞色素P450和SLCO1B1酶及药物不良事件：一项非实验性观察性研究。
Medicine (Baltimore). 2025 Apr 4;104(14):e42031. doi: 10.1097/MD.0000000000042031.
3
Association of gene variants with angiotensin-converting enzyme inhibitor-induced cough in a Pakistani hypertensive cohort.巴基斯坦高血压队列中基因变异与血管紧张素转换酶抑制剂引起的咳嗽的关联
Front Pharmacol. 2024 Sep 4;15:1441251. doi: 10.3389/fphar.2024.1441251. eCollection 2024.
4
Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients.64000名英国生物银行患者的外显子组测序与他汀类药物治疗反应
Int J Mol Sci. 2024 Apr 17;25(8):4426. doi: 10.3390/ijms25084426.
5
Identification of Drugs Acting as Perpetrators in Common Drug Interactions in a Cohort of Geriatric Patients from Southern Italy and Analysis of the Gene Polymorphisms That Affect Their Interacting Potential.意大利南部老年患者队列中常见药物相互作用中作为肇事者的药物鉴定以及影响其相互作用潜力的基因多态性分析。
Geriatrics (Basel). 2023 Aug 24;8(5):84. doi: 10.3390/geriatrics8050084.
6
SLCO1B1*5 is protective against non-senile cataracts in cohort prescribed statins: analysis in a British-South Asian cohort.SLCO1B1*5 可预防队列中服用他汀类药物的非老年白内障：在英国南亚人群中的分析。
Pharmacogenomics J. 2023 Sep;23(5):134-139. doi: 10.1038/s41397-023-00307-w. Epub 2023 May 23.
7
Case report: Hepatotoxicity and nephrotoxicity induced by methotrexate in a paediatric patient, what is the role of precision medicine in 2023?病例报告：甲氨蝶呤引起的一名儿科患者的肝毒性和肾毒性，精准医学在2023年的作用是什么？
Front Pharmacol. 2023 May 2;14:1130548. doi: 10.3389/fphar.2023.1130548. eCollection 2023.
8
Regulation of Human Endogenous Metabolites by Drug Transporters and Drug Metabolizing Enzymes: An Analysis of Targeted SNP-Metabolite Associations.药物转运体和药物代谢酶对人内源性代谢物的调控：靶向单核苷酸多态性-代谢物关联分析
Metabolites. 2023 Jan 24;13(2):171. doi: 10.3390/metabo13020171.
9
Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters.转运体和代谢酶基因多态性影响氟喹诺酮类药物的药代动力学参数。
Front Pharmacol. 2022 Dec 12;13:1063413. doi: 10.3389/fphar.2022.1063413. eCollection 2022.
10
Genetically personalised organ-specific metabolic models in health and disease.在健康和疾病中具有个性化遗传特征的器官特异性代谢模型。
Nat Commun. 2022 Nov 29;13(1):7356. doi: 10.1038/s41467-022-35017-7.
本文引用的文献
1
Genome-wide association meta-analysis for total serum bilirubin levels.全基因组关联荟萃分析血清总胆红素水平
Hum Mol Genet. 2009 Jul 15;18(14):2700-10. doi: 10.1093/hmg/ddp202. Epub 2009 May 4.
2
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.伊立替康所致中性粒细胞减少症及药代动力学的综合药物遗传学分析
J Clin Oncol. 2009 Jun 1;27(16):2604-14. doi: 10.1200/JCO.2008.20.6300. Epub 2009 Apr 6.
3
Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.吉非贝齐和阿托伐他汀对瑞格列奈药代动力学的影响与溶质载体有机阴离子转运体1B1（SLCO1B1）基因多态性的关系
Clin Pharmacol Ther. 2008 Oct;84(4):488-96. doi: 10.1038/clpt.2008.74.
4
Genetic variations of the SLCO1B1 gene in the Chinese, Malay and Indian populations of Singapore.新加坡华裔、马来裔和印度裔人群中SLCO1B1基因的遗传变异。
Drug Metab Pharmacokinet. 2008;23(6):476-82. doi: 10.2133/dmpk.23.476.
5
Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.在接受基于伊立替康的化疗后，一名UGT1A1*6/*28和SLCO1B1*15/*15基因型患者出现危及生命的毒性反应。
Cancer Chemother Pharmacol. 2009 May;63(6):1165-9. doi: 10.1007/s00280-008-0864-x. Epub 2008 Nov 8.
6
The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.SLCO1B1基因多态性对瑞格列奈药代动力学的影响在很宽的剂量范围内持续存在。
Br J Clin Pharmacol. 2008 Dec;66(6):818-25. doi: 10.1111/j.1365-2125.2008.03287.x. Epub 2008 Sep 23.
7
Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.编码OATP1B1的基因的常见等位基因与氟伐他汀治疗后LDL降低反应增强之间的关联。
Pharmacogenomics. 2008 Sep;9(9):1217-27. doi: 10.2217/14622416.9.9.1217.
8
Amino acid residues in transmembrane domain 10 of organic anion transporting polypeptide 1B3 are critical for cholecystokinin octapeptide transport.有机阴离子转运多肽1B3跨膜结构域10中的氨基酸残基对胆囊收缩素八肽的转运至关重要。
Biochemistry. 2008 Sep 2;47(35):9090-7. doi: 10.1021/bi8008455. Epub 2008 Aug 9.
9
SLCO1B1 variants and statin-induced myopathy--a genomewide study.溶质载体有机阴离子转运体家族1成员B1（SLCO1B1）变异与他汀类药物诱发的肌病——一项全基因组研究
N Engl J Med. 2008 Aug 21;359(8):789-99. doi: 10.1056/NEJMoa0801936. Epub 2008 Jul 23.
10
Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism.普伐他汀与奥美沙坦之间的药代动力学相互作用与溶质载体有机阴离子转运体1B1（SLCO1B1）基因多态性的关系。
J Hum Genet. 2008;53(10):899-904. doi: 10.1007/s10038-008-0324-9. Epub 2008 Jul 19.
Zotero 插件